ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Vaginal progesterone and the risk of preterm birth in patients with short cervix beyond 24 weeks.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vaginal progesterone and the risk of preterm birth in patients with short cervix beyond 24 weeks.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe efficacy of vaginal progesterone (VP) in preventing spontaneous preterm birth (sPTB) among women with a mid-trimester short cervix is well established. However, data regarding prevention of sPTB using VP beyond 24 weeks are limited and inconclusive. The aim of the present study was to evaluate the association of VP on the risk of sPTB in women diagnosed with a cervical length (CL) <25 mm beyond 24 weeks.
methodsThis retrospective cohort study included women with singleton pregnancies, no history of prior PTB and CL <25 mm diagnosed between 24
resultsAmong 890 eligible women, 490 received VP, and 400 did not. Women in the VP group were diagnosed earlier (29.5 ± 2.8 vs. 31.4 ± 2.4 weeks, P < 0.001) and had shorter CL (17.5 ± 5.3 vs. 19.8 ± 5 mm, P < 0.001). Logistic regression and 1:1 matched analysis, adjusted for gestational age at diagnosis and CL, showed no significant effect of VP on the risk of sPTB at <37, <34, <32, or <28 weeks. The mean interval from diagnosis to delivery was similar between groups (48.6 ± 24.0 vs. 49.5 ± 24.6 days, P = 0.57). Subgroup analysis showed no benefit of VP in asymptomatic women or those with arrested preterm labor.
conclusionIn women with a singleton pregnancy, no history of prior PTB and a short cervix diagnosed after 24 weeks, VP was not associated with reduced sPTB risk or prolonged pregnancy duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.